Jusmiral Holdings Limited, the promoter of Cohance Lifesciences Limited , has declared that it has not created any encumbrance on the company's shares during the financial year 2025-26. The disclosure, submitted to the stock exchanges, confirms that no direct or indirect charges were placed on the shares other than those previously disclosed. This assurance provides clarity to shareholders regarding the status of the promoter's holding amidst regulatory compliance requirements.

The declaration was made pursuant to Regulation 31(4) of the SEBI (Substantial Acquisition of Shares & Takeover) Regulations, 2011. Jusmiral Holdings Limited, along with persons acting in concert—specifically Berhyanda Limited and Jusmiral Midco Limited—formally communicated this status to the Manager of the Department of Corporate Services at BSE Limited and the Manager of the Listing Department at National Stock Exchange of India Limited.

Regulatory Filing Details

The communication addressed to the exchanges explicitly stated that the promoter group has not made any fresh encumbrance on the shares of Cohance Lifesciences Limited. The filing serves as a formal update to the records of the exchanges and the Audit Committee of the company.

Key Entities Involved

The letter, dated April 7, 2026, was signed by Christodoulos Patsalides, Director of Jusmiral Holdings Limited. A copy of the declaration was also forwarded to the Audit Committee of Cohance Lifesciences Limited for their information and records.

Cohance Lifesciences Limited has announced its intention to seek approval from the Central Government for the appointment of Mr. Umang Vohra as a Director and Chairman of the company. This strategic leadership change, effective from May 1, 2026, is subject to regulatory consent under Section 196 read with Part I of Schedule V of the Companies Act, 2013.

The company's Board of Directors had approved the appointment at its meeting held on April 27, 2026. Subsequently, the members of the company accorded their approval through a postal ballot conducted on June 13, 2026. The proposed tenure for Mr. Vohra extends until April 30, 2031, during which he will not be liable to retire by rotation.

Mr. Umang Vohra, identified as a Non-Resident with DIN 02296740, is also designated to take on the role of Group Chief Executive Officer effective May 20, 2026. The notice regarding this application was published in newspapers on June 26, 2026, in compliance with Section 201 of the Companies Act, 2013.

The company has ensured that the requisite information is available to shareholders and has been hosted on its official website. The move to appoint a new chairman and CEO comes as the company continues to operate under its former identity, Suven Pharmaceuticals Limited, during the transition period.